Osteoprotegerin promotes vascular fibrosis via a TGF-β1 autocrine loop

Atherosclerosis

Volumn 218, Issue 1, 2011, Pages 61-68

  Toffoli, Barbara ^a   Pickering, Raelene J ^b   Tsorotes, Despina ^b   Wang, Bo ^b   Bernardi, Stella ^b   Kantharidis, Phillip ^b   Fabris, Bruno ^c   Zauli, Giorgio ^a   Secchiero, Paola ^d   Thomas, Merlin C ^b  

^a INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c UNIVERSITY OF TRIESTE   (Italy)

^d UNIVERSITY OF FERRARA   (Italy)

Author keywords

Atherosclerosis; OPG; TGF 1; VSMC

Indexed keywords

ANGIOTENSIN II; COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGEN TYPE 4; CYTOKINE; FIBRONECTIN; GELATINASE A; GELATINASE B; OSTEOPROTEGERIN; PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; FIBROSIS; INFLAMMATION; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; VASCULAR FIBROSIS; VASCULAR SMOOTH MUSCLE;

ANIMALS; APOLIPOPROTEINS E; CELL PROLIFERATION; COLLAGEN; FIBRONECTINS; FIBROSIS; GENE EXPRESSION REGULATION; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; OSTEOPROTEGERIN; PLATELET-DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA1;

EID: 80052263610     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.05.019     Document Type: Article

References (35)

1. Zauli G., Melloni E., Capitani S., Secchiero P. Role of full-length osteoprotegerin in tumor cell biology. Cell Mol Life Sci 2009, 66:841-851.
2. Abedin M., Omland T., Ueland T., et al. Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). Am J Cardiol 2007, 99:513-518.
3. Olesen P., Ledet T., Rasmussen L.M. Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-α. Diabetologia 2005, 48:561-568.
4. Zagura M., Serg M., Kampus P., et al. Association of osteoprotegerin with aortic stiffness in patients with symptomatic peripheral artery disease and in healthy subjects. Am J Hypertens 2010, 23:586-591.
5. Ziegler S., Kudlacek S., Luger A., Minar E. Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis 2005, 182:175-180.
6. Omland T., Ueland T., Jansson A.M., et al. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol 2008, 51:627-633.
7. Ueland T., Jemtland R., Godang K., et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol 2004, 44:1970-1976.
8. Secchiero P., Corallini F., Pandolfi A., et al. An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am J Pathol 2006, 169:2236-2244.
9. Jorsal A., Tarnow L., Flyvbjerg A., Parving H.H., Rossing P., Rasmussen L.M. Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy. Diabetologia 2008, 51:2100-2107.
10. Candido R., Toffoli B., Corallini F., et al. Human full-length osteoprotegerin induces the proliferation of rodent vascular smooth muscle cells both in vitro and in vivo. J Vasc Res 2010, 47:252-261.
11. Secchiero P., Corallini F., di Iasio M.G., Gonelli A., Barbarotto E., Zauli G. TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release. Blood 2005, 105:3413-3419.
12. Secchiero P., Candido R., Corallini F., et al. Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null diabetic mice. Circulation 2006, 114:1522-1530.
13. Mangan S.H., Van Campenhout A., Rush C., Golledge J. Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-alpha associated with induction of angiopoietin-2. Cardiovasc Res 2007, 76:494-505.
14. Zauli G., Corallini F., Bossi F., et al. Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. Blood 2007, 110:536-543.
15. Milani D., Zauli G., Rimondi E., et al. Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells. J Neurochem 2003, 86:126-135.
16. Secchiero P., Sun D., De Vico A.L., et al. Role of the extracellular domain of human herpesvirus 7 glycoprotein B in virus binding to cell surface heparan sulfate proteoglycans. J Virol 1997, 71:4571-4580.
17. Secchiero P., Corallini F., Beltrami A.P., et al. An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction. Atherosclerosis 2010, 210:274-277.
18. Semb A.G., Ueland T., Aukrust P., et al. Osteoprotegerin and soluble receptor activator of nuclear factor-B ligand and risk for coronary events. Arterioscler Thromb Vasc Biol 2009, 29:975-980.
19. Szulc P., Hofbauer L.C., Heufelder A.E., Roth S., Delmas P.D. Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. J Clin Endocrinol Metab 2001, 86:3162-3165.
20. Lipton A., Ali S.M., Leitzel K., et al. Serum osteoprotegerin levels in healthy controls and cancer patients. Clin Cancer Res 2002, 8:2306-2310.
21. Kudlacek S., Schneider B., Woloszczuk W., Pietschmann P., Willvonseder R. Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone 2003, 32:681-686. Austrian Study Group on Normative Values of Bone Metabolism.
22. Gibbons G.H., Pratt R.E., Dzau V.J. Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. J Clin Invest 1992, 90:456-461.
23. Moran C.S., Cullen B., Campbell J.H., Golledge J. Interaction between angiotensin II, osteoprotegerin, and peroxisome proliferator-activated receptor-gamma in abdominal aortic aneurysm. J Vasc Res 2009, 46:209-217.
24. Zhang J., Fu M., Myles D., et al. PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Lett 2002, 52:180-184.
25. Moran C.S., McCann M., Karan M., Norman P., Ketheesan N., Golledge J. Association of osteoprotegerin with human abdominal aortic aneurysm progression. Circulation 2005, 111:3119-3125.
26. Thirunavukkarasu K., Miles R.R., Halladay D.L., et al. Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. J Biol Chem 2001, 276:36241-36250.
27. Simionescu A., Simionescu D.T., Vyavahare N.R. Osteogenic responses in fibroblasts activated by elastin degradation products and transforming growth factor-beta1: role of myofibroblasts in vascular calcification. Am J Pathol 2007, 171:116-123.
28. Nguyen K.Q., Olesen P., Ledet T., Rasmussen L.M. Bone morphogenetic proteins regulate osteoprotegerin and its ligands in human vascular smooth muscle cells. Endocrine 2007, 32:52-58.
29. Karst M., Gorny G., Galvin R.J., Oursler M.J. Roles of stromal cell RANKL, OPG, and M-CSF expression in biphasic TGF-beta regulation of osteoclast differentiation. J Cell Physiol 2004, 200:99-106.
30. Nishio E., Watanabe Y. Transforming growth factor beta is a modulator of platelet-derived growth factor action in vascular smooth muscle cells: a possible role for catalase activity and glutathione peroxidase activity. Biochem Biophys Res Commun 1997, 232:1-4.
31. Rekhter M.D. Collagen synthesis in atherosclerosis: too much and not enough. Cardiovasc Res 1999, 41:376-384.
32. Ovchinnikova O., Gylfe A., Bailey L., et al. Osteoprotegerin promotes fibrous cap formation in atherosclerotic lesions of ApoE-deficient mice-brief report. Arterioscler Thromb Vasc Biol 2009, 29:1478-1480.
33. Grainger D.J. TGF-beta and atherosclerosis in man. Cardiovasc Res 2007, 74:213-222.
34. Shaker O.G., El-Shehaby A., Nabih M. Possible role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand as markers of plaque instability in coronary artery disease. Angiology 2010, 61:756-762.
35. Bucay N., Sarosi I., Dunstan C.R., et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998, 12:1260-1268.